The Journal of Immunology, Vol 153, Issue 5 2239-2247, Copyright © 1994 by American Association of Immunologists

ARTICLES

Inhibition of lipopolysaccharide and IL-1 but not of TNF-induced activation of human endothelial cells by suramin

G Strassmann, N Graber, SM Goyert, M Fong, S McCullers, GW Rong and LD Beall
Department of Immunology, Otsuka America Pharmaceutical Inc., Rockville, MD 20850.

The binding and trans-endothelium migration of inflammatory cells is believed to play a critical role in a variety of inflammatory conditions. This study investigates the ability of the experimental drug suramin to block the activation of HUVEC by endotoxin and by the proinflammatory cytokines IL-1 and TNF. We demonstrate that the inducible expression of several adhesion molecules by LPS and IL-1 beta but not by TNF-alpha is prevented by suramin. In a dose-dependent manner, suramin inhibits the binding of neutrophils and T lymphocytes to LPS and IL-1 beta but not to TNF-alpha-activated HUVEC. The inhibitory effect of the drug on IL-1 beta-induced but not on LPS- induced cell stimulation can be completely reversed by the addition of excess cytokine but not by excess LPS. Because LPS activation of HUVEC is known to depend on serum/plasma-derived soluble CD14, we set out to determine whether suramin inhibition involves interference with the action of the CD14-LPS complex on HUVEC. Indeed, the drug prevents the binding of radioactive LPS in the presence of serum and inhibits LPS- induced cell activation in serum-free medium supplemented with recombinant soluble CD14. The results suggest that suramin interferes with the CD14-dependent activation of HUVEC and that it also may be a useful agent in blocking infectious endotheliopathies in vivo.

This article has been cited by other articles:

				F. C Tanner, D. P Carr, G. J Nabel, and E. G Nabel Transfection of human endothelial cells Cardiovasc Res, September 1, 1997; 35(3): 522 - 528. [Abstract] [Full Text] [PDF]